{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:08:48Z","timestamp":1784696928595,"version":"3.55.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.tox.2011.08.006","type":"journal-article","created":{"date-parts":[[2011,8,14]],"date-time":"2011-08-14T18:32:03Z","timestamp":1313346723000},"page":"122-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity"],"prefix":"10.1016","volume":"289","author":[{"given":"Pavl\u00edna","family":"Ha\u0161kov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Koubkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"V\u00e1vrov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli\u0161ka","family":"Mackov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate\u0159ina","family":"Hru\u0161kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Kova\u0159\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate\u0159ina","family":"V\u00e1vrov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"\u0160im\u016fnek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tox.2011.08.006_bib0005","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1139\/Y09-042","article-title":"Role of the excessive amounts of circulating catecholamines and glucocorticoids in stress-induced heart disease","volume":"87","author":"Adameova","year":"2009","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.tox.2011.08.006_bib0010","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/ajh.21487","article-title":"Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil","volume":"84","author":"Al-Rousan","year":"2009","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tox.2011.08.006_bib0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.tox.2010.05.003","article-title":"Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats","volume":"274","author":"Arozal","year":"2010","journal-title":"Toxicology"},{"key":"10.1016\/j.tox.2011.08.006_bib0020","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0891-5849(02)00873-0","article-title":"Deferiprone protects against doxorubicin-induced myocyte cytotoxicity","volume":"33","author":"Barnabe","year":"2002","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.tox.2011.08.006_bib0025","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1021\/tx100125t","article-title":"Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury","volume":"23","author":"Bendova","year":"2010","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tox.2011.08.006_bib0030","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1111\/j.1471-4159.1991.tb11444.x","article-title":"The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons","volume":"56","author":"Ben-Shachar","year":"1991","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tox.2011.08.006_bib0035","first-page":"H1372","article-title":"The iron chelator desferrioxamine attenuates postischemic ventricular dysfunction","volume":"253","author":"Bolli","year":"1987","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.tox.2011.08.006_bib0040","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2009-05-222729","article-title":"Deferasirox pharmacokinetics in patients with adequate versus inadequate response","volume":"114","author":"Chirnomas","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.tox.2011.08.006_bib0310","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2174\/092986711795656081","article-title":"Contribution of catecholamine reactive intermediates and oxidative stress to the pathologic features of heart diseases","volume":"18","author":"Costa","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.tox.2011.08.006_bib0050","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/10715769409147506","article-title":"The action of nine chelators on iron-dependent radical damage","volume":"20","author":"Dean","year":"1994","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.tox.2011.08.006_bib0055","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1472-8206.2010.00836.x","article-title":"Role of catecholamine oxidation in sudden cardiac death","volume":"24","author":"Dhalla","year":"2010","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.tox.2011.08.006_bib0060","first-page":"259","article-title":"Ameliorative effects of ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the cardiotoxicity induced by doxorubicin or by isoproterenol in the mouse","volume":"70","author":"Flandina","year":"1990","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"key":"10.1016\/j.tox.2011.08.006_bib0065","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2174\/1389557013406846","article-title":"Recent advances in the design of iron chelators against oxidative damage","volume":"1","author":"Galey","year":"2001","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.tox.2011.08.006_bib0070","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/clinchem\/40.2.250","article-title":"Urinary and plasma catecholamines and urinary catecholamine metabolites in pheochromocytoma: diagnostic value in 19 cases","volume":"40","author":"Gerlo","year":"1994","journal-title":"Clin. Chem."},{"key":"10.1016\/j.tox.2011.08.006_bib0075","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1124\/jpet.103.049270","article-title":"Sources and significance of plasma levels of catechols and their metabolites in humans","volume":"305","author":"Goldstein","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tox.2011.08.006_bib0080","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1016\/S0021-9258(17)43139-5","article-title":"Iron-catalyzed hydroxyl radical formation. Stringent requirement for free iron coordination site","volume":"259","author":"Graf","year":"1984","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tox.2011.08.006_bib0085","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jacc.2010.03.083","article-title":"Iron overload cardiomyopathy: better understanding of an increasing disorder","volume":"56","author":"Gujja","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.tox.2011.08.006_bib0090","series-title":"Free Radicals in Biology and Medicine","author":"Halliwell","year":"2007"},{"key":"10.1016\/j.tox.2011.08.006_bib0095","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1385\/CT:2:2:111","article-title":"Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage","volume":"2","author":"Hasinoff","year":"2002","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.tox.2011.08.006_bib0100","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.freeradbiomed.2010.12.004","article-title":"Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autooxidation and cardiotoxicity","volume":"50","author":"Haskova","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.tox.2011.08.006_bib0105","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1196\/annals.1345.015","article-title":"Objectives and mechanism of iron chelation therapy","volume":"1054","author":"Hershko","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.tox.2011.08.006_bib0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2002-06-1867","article-title":"Role of deferiprone in chelation therapy for transfusional iron overload","volume":"102","author":"Hoffbrand","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.tox.2011.08.006_bib0115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.tox.2011.03.001","article-title":"Advances in metal-induced oxidative stress and human disease","volume":"283","author":"Jomova","year":"2011","journal-title":"Toxicology"},{"key":"10.1016\/j.tox.2011.08.006_bib0120","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/pr.57.4.2","article-title":"The evolution of iron chelators for the treatment of iron overload disease and cancer","volume":"57","author":"Kalinowski","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.tox.2011.08.006_bib0125","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00204-010-0577-x","article-title":"Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples","volume":"84","author":"Kell","year":"2010","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.tox.2011.08.006_bib0130","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0014-4827(76)90447-X","article-title":"Properties of a clonal muscle cell line from rat heart","volume":"98","author":"Kimes","year":"1976","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.tox.2011.08.006_bib0135","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.chroma.2010.11.050","article-title":"Hydrophilic interaction liquid chromatography in the separation of a moderately lipophilic drug from its highly polar metabolites\u2014the cardioprotectant dexrazoxane as a model case","volume":"1218","author":"Kovarikova","year":"2011","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.tox.2011.08.006_bib0140","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCHEARTFAILURE.109.913863","article-title":"Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives","volume":"3","author":"Kremastinos","year":"2010","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.tox.2011.08.006_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0098-2997(00)00006-6","article-title":"The roles of iron in health and disease","volume":"22","author":"Lieu","year":"2001","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.tox.2011.08.006_bib0150","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/mol.108.046847","article-title":"Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class","volume":"74","author":"Lim","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tox.2011.08.006_bib0155","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/0960327109350665","article-title":"Cardiac biomarkers in a model of acute catecholamine cardiotoxicity","volume":"28","author":"Mladenka","year":"2009","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.tox.2011.08.006_bib0160","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1021\/tx800331j","article-title":"The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity","volume":"22","author":"Mladenka","year":"2009","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tox.2011.08.006_bib0165","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/10715760500511484","article-title":"The role of reactive oxygen and nitrogen species in cellular iron metabolism","volume":"40","author":"Mladenka","year":"2006","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.tox.2011.08.006_bib0170","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1111\/j.1471-4159.2008.05332.x","article-title":"Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells","volume":"105","author":"Molina-Holgado","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tox.2011.08.006_bib0175","doi-asserted-by":"crossref","first-page":"358","DOI":"10.5414\/CPP47358","article-title":"Bioequivalence study of a film-coated tablet of deferiprone in healthy Thai volunteers","volume":"47","author":"Morales","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.tox.2011.08.006_bib0180","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.V89.3.739","article-title":"Iron-chelating therapy and the treatment of thalassemia","volume":"89","author":"Olivieri","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.tox.2011.08.006_bib0185","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/sj.bjc.6605192","article-title":"Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death","volume":"101","author":"Popelova","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tox.2011.08.006_bib0190","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/jpet.108.137604","article-title":"Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo","volume":"326","author":"Popelova","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tox.2011.08.006_bib0195","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.tox.2007.01.006","article-title":"Preventive effect of naringin on isoproterenol-induced cardiotoxicity in Wistar rats: an in vivo and in vitro study","volume":"232","author":"Rajadurai","year":"2007","journal-title":"Toxicology"},{"key":"10.1016\/j.tox.2011.08.006_bib0200","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/cvr\/25.9.711","article-title":"Pretreatment with the iron chelator desferrioxamine fails to provide sustained protection against myocardial ischaemia-reperfusion injury","volume":"25","author":"Reddy","year":"1991","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.tox.2011.08.006_bib0205","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0891-5849(92)90091-T","article-title":"Ferritin as a source of iron for oxidative damage","volume":"12","author":"Reif","year":"1992","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.tox.2011.08.006_bib0210","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1021\/tx025518q","article-title":"Cu2+-induced isoproterenol oxidation into isoprenochrome in adult rat calcium-tolerant cardiomyocytes","volume":"15","author":"Remiao","year":"2002","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tox.2011.08.006_bib0215","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nprot.2008.75","article-title":"Neutral red uptake assay for the estimation of cell viability\/cytotoxicity","volume":"3","author":"Repetto","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.tox.2011.08.006_bib0220","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2261-5-32","article-title":"EDTA chelation therapy for cardiovascular disease: a systematic review","volume":"5","author":"Seely","year":"2005","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.tox.2011.08.006_bib0225","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.yjmcc.2005.05.008","article-title":"SIH\u2014a novel lipophilic iron chelator\u2014protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death","volume":"39","author":"Simunek","year":"2005","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.tox.2011.08.006_bib0230","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10534-004-4491-7","article-title":"Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits","volume":"18","author":"Simunek","year":"2005","journal-title":"Biometals"},{"key":"10.1016\/j.tox.2011.08.006_bib0235","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1734-1140(09)70018-0","article-title":"Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron","volume":"61","author":"Simunek","year":"2009","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.tox.2011.08.006_bib0240","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/bjp.2008.236","article-title":"Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone","volume":"155","author":"Simunek","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tox.2011.08.006_bib0245","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.yjmcc.2004.05.024","article-title":"Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro","volume":"37","author":"Spallarossa","year":"2004","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.tox.2011.08.006_bib0250","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.tins.2007.03.009","article-title":"Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease","volume":"30","author":"Sulzer","year":"2007","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.tox.2011.08.006_bib0255","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2141.1979.tb01167.x","article-title":"Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects","volume":"42","author":"Summers","year":"1979","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tox.2011.08.006_bib0260","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/ars.2006.8.197","article-title":"Oxidative stress, accumulation of biological \u2018garbage\u2019, and aging","volume":"8","author":"Terman","year":"2006","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.tox.2011.08.006_bib0265","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2174\/0929867053764635","article-title":"Metals, toxicity and oxidative stress","volume":"12","author":"Valko","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.tox.2011.08.006_bib0270","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1161\/01.CIR.80.1.158","article-title":"Prevention of postischemic cardiac injury by the orally active iron chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3","volume":"80","author":"van der Kraaij","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.tox.2011.08.006_bib0275","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1172\/JCI116086","article-title":"Low molecular weight iron and the oxygen paradox in isolated rat hearts","volume":"90","author":"Voogd","year":"1992","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tox.2011.08.006_bib0280","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0891-5849(99)00107-0","article-title":"Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader","volume":"27","author":"Wang","year":"1999","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.tox.2011.08.006_bib0285","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1006\/jsre.1993.1180","article-title":"Failure of deferoxamine to reduce myocardial infarct size in a primate model of ischemia-reperfusion injury","volume":"55","author":"Watanabe","year":"1993","journal-title":"J. Surg. Res."},{"issue":"Suppl. 2","key":"10.1016\/j.tox.2011.08.006_bib0290","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S0268-960X(08)70004-3","article-title":"Cardiac iron across different transfusion-dependent diseases","volume":"22","author":"Wood","year":"2008","journal-title":"Blood Rev."},{"issue":"Suppl. 1","key":"10.1016\/j.tox.2011.08.006_bib0295","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.3109\/03630260903347526","article-title":"Cardiac complications in thalassemia major","volume":"33","author":"Wood","year":"2009","journal-title":"Hemoglobin"},{"key":"10.1016\/j.tox.2011.08.006_bib0300","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1196\/annals.1345.047","article-title":"Physiology and pathophysiology of iron cardiomyopathy in thalassemia","volume":"1054","author":"Wood","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.tox.2011.08.006_bib0305","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0735-1097(02)02935-2","article-title":"Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes","volume":"41","author":"Yamanaka","year":"2003","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X11002976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X11002976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T23:16:44Z","timestamp":1759533404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300483X11002976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":61,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0300483X11002976"],"URL":"https:\/\/doi.org\/10.1016\/j.tox.2011.08.006","relation":{},"ISSN":["0300-483X"],"issn-type":[{"value":"0300-483X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity","name":"articletitle","label":"Article Title"},{"value":"Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tox.2011.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}